Myriad Genetics (NASDAQ:MYGN – Get Free Report) is one of 842 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Myriad Genetics to similar companies based on the strength of its institutional ownership, dividends, profitability, analyst recommendations, risk, earnings and valuation.
Insider & Institutional Ownership
99.0% of Myriad Genetics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 1.9% of Myriad Genetics shares are owned by insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Myriad Genetics and its rivals gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Myriad Genetics | $824.50 million | -$365.90 million | -4.02 |
| Myriad Genetics Competitors | $688.58 million | $7.69 million | -17.98 |
Myriad Genetics has higher revenue, but lower earnings than its rivals. Myriad Genetics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Risk & Volatility
Myriad Genetics has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500. Comparatively, Myriad Genetics’ rivals have a beta of -1.85, suggesting that their average stock price is 285% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations for Myriad Genetics and its rivals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Myriad Genetics | 1 | 7 | 1 | 0 | 2.00 |
| Myriad Genetics Competitors | 9951 | 15359 | 45765 | 1602 | 2.54 |
Myriad Genetics presently has a consensus target price of $5.98, suggesting a potential upside of 9.40%. As a group, “Biotechnology” companies have a potential upside of 114.74%. Given Myriad Genetics’ rivals stronger consensus rating and higher probable upside, analysts clearly believe Myriad Genetics has less favorable growth aspects than its rivals.
Profitability
This table compares Myriad Genetics and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Myriad Genetics | -16.07% | -19.87% | -9.67% |
| Myriad Genetics Competitors | -12,224.75% | -204.85% | -31.52% |
Summary
Myriad Genetics beats its rivals on 7 of the 13 factors compared.
Myriad Genetics Company Profile
Myriad Genetics, Inc. is a molecular diagnostics company that develops and provides genetic tests to help inform healthcare decisions. Its offerings include tests for hereditary cancer risk, tumor biology and prognosis, reproductive health, and how patients may respond to certain medications. Its products include MyRisk, which assesses inherited cancer risk; GeneSight, a pharmacogenomic test intended to help guide psychiatric medication decisions; and Prolaris, which helps assess the aggressiveness of prostate cancer.
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
